Here's an example of an oncology drug (prostate) that was recently fast tracked by the FDA.
It was stopped mid phase 3. It demonstrated a 4.8 month median OS benefit and 5.4mnth PFS. This is a lower benefit than I would have thought to stop the trial early, but due to it's low toxicity it was approved.
http://www.clinicalleader.com/doc.mvc/xtandi-gets-speedy-fda-ok-metastatic-castration-prostate-cancer-0001
benefits of priority review and orphan status
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.015(5.08%) |
Mkt cap ! $450.3M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 35.0¢ | 31.0¢ | $2.508M | 7.793M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 226373 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 40135 | 2 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |